Business
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated, CDK4/6-experienced patients (median third-line); ORR is similar across kinase and non-kinase PIK3CA mutations Phase 3 frontline trial in endocrine sensitive patients expected to initiate in early 2027, subject to regulatory feedback Supply agreement in place with Pfizer to supply atirmociclib
About this update from Relay Therapeutics, Inc.
[{"type":"image","alt":"Relay Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Relay Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":131,"url":"https://media.zenfs.com/en/globenewswire.com/9a37786351f2b419db7f6dccc70bf15f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Vu9j.OPRikxfmERBKVL9VQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4Mw--/https://media.zenfs.com/en/globenewswire.com/9a37786351f2b419db7f6dccc70bf15f","width":300,"height":131}},"lazy":false},{"type":"text","content":"Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development","length":85,"tagName":"p"},{"type":"text","content":"Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients","length":87,"tagName":"p"},{"type":"text","content":"44% ORR in heavily pre-treated, CDK4/6-experienced patients (median third-line); ORR is similar across kinase and non-kinase PIK3CA mutations","length":141,"tagName":"p"},{"type":"text","content":"Phase 3 frontline trial in endocrine sensitive patients expected to initiate in early 2027, subject to regulatory feedback","length":122,"tagName":"p"},{"type":"text","content":"Supply agreement in place with Pfizer to supply atirmociclib for the Phase 3 frontline trial","length":92,"tagName":"p"},{"type":"text","content":"Relay Therapeutics to host a conference call today, April 27, at 8:30am ET","length":74,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced plans to move zovegalisib + atirmociclib, Pfizer’s investigational, potential first-in-class CDK4 inhibitor, into Phase 3 development for frontline patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.","length":482,"tagName":"p"},{"type":"text","content":"“While PI3Kα inhibition has demonstrated meaningful benefit in breast cancer, its use in the frontline setting has been limited by tolerability challenges with earlier agents,” said Don Bergstrom, M.D., Ph.D., President of R&D at Relay Therapeutics. “We believe that combining the selective profiles of zovegalisib and atirmociclib with endocrine therapy has the ...